David T Yang

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
    David T Yang
    Department of Pharmacology, University of Wisconsin School of Medicine and Public Health, Madison, USA
    Mol Cancer 7:40. 2008
  2. ncbi Use of tissue microarray and automated quantitative analysis for screening and validation of potential biomarkers in mantle cell lymphoma
    David T Yang
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, USA
    Appl Immunohistochem Mol Morphol 19:62-9. 2011
  3. ncbi VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study
    Julie E Chang
    Department of Medicine, School of Medicine and Public Health, The UW Carbone Cancer Center, University of Wisconsin, Madison, WI 53705, USA
    Br J Haematol 155:190-7. 2011

Collaborators

  • Brad Kahl
  • Shigeki Miyamoto
  • Julie E Chang
  • Walter L Longo
  • Michael Volk
  • Sangbum Choi
  • Jules Blank
  • Jae E Werndli
  • Christopher Peterson
  • Thomas A McFarland
  • Eric S Rogers
  • Jens C Eickhoff
  • Natalie S Callander
  • Michael S Huie
  • Leslie A Gilbert
  • Kyungmann Kim

Detail Information

Publications3

  1. ncbi Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
    David T Yang
    Department of Pharmacology, University of Wisconsin School of Medicine and Public Health, Madison, USA
    Mol Cancer 7:40. 2008
    ..While MCL cells have been shown to harbor constitutive NF-kappaB activity, what fraction of this activity in primary MCL samples is sensitive or resistant to inhibition by bortezomib remains unclear...
  2. ncbi Use of tissue microarray and automated quantitative analysis for screening and validation of potential biomarkers in mantle cell lymphoma
    David T Yang
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, USA
    Appl Immunohistochem Mol Morphol 19:62-9. 2011
    ....
  3. ncbi VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study
    Julie E Chang
    Department of Medicine, School of Medicine and Public Health, The UW Carbone Cancer Center, University of Wisconsin, Madison, WI 53705, USA
    Br J Haematol 155:190-7. 2011
    ..The observed 3-year PFS and OS with VcR-CVAD in MCL were comparable to reported outcomes with more intensive regimens. A cooperative group trial (E1405) is attempting to replicate these promising results...